Clinical trial
A Phase 1/2 Study of DENSPM (N1, N11-diethylnorspermine) in Patients With Unresectable Hepatocellular Carcinoma
NCT00081900 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of DENSPM (N1, N11-diethylnorspermine) in Patients With Unresectable Hepatocellular Carcinoma
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- March 31, 2004
- Completion date
- November 30, 2007
- Enrollment
- 38 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.